http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2530584-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_418233897133ecc4cef8adfb8c6353f4 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-49 |
| filingDate | 2012-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cfdf0f3d7a3c82e8a51a075bcfc4774 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33a4a44e9c80af8685e8392513be4609 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0f66e6475bf8544d60b3ab00fc7ece6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a46770884a9e7116700e4652076070ea |
| publicationDate | 2014-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2530584-C2 |
| titleOfInvention | Method for testing anticoagulant activity of blood |
| abstract | FIELD: medicine. n SUBSTANCE: invention refers to medicine, namely to testing the anticoagulant activity of blood. Substance of the method consists in performing low-frequency piezothromboelastography and measuring blood viscosity characteristics: A0 is an initial blood state of aggregate, A1 is a value describing the maximum change of the blood state of aggregate at the stage of contact activation, A3 is a value describing the blood state of aggregate at the stage of the beginning of the polymerization process, t3 is the time to reach A3, A4 is a value describing the blood state of aggregate 10 min after the A3 value is achieved, t4 is always 10 minutes, as well as a clot polymerisation intensity (CPI); a coefficient of the anticoagulant activity of blood (AAB) is calculated by formula. If the AAB value falls within the range of 1.5-2, the normal anticoagulant activity is stated, while the AAB values less than 1.5 shows the decreased anticoagulant activity. n EFFECT: using the method enables monitoring the anticoagulant activity of blood both at the stage of diagnosing, and at any stage of therapy of haemostatic disorders with high accuracy and reliability by carrying out the integrated assessment of the anticoagulant activity of blood. n 1 tbl, 1 dwg, 2 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2690856-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2571505-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2648032-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2634567-C1 |
| priorityDate | 2012-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 95.